Reform needed to give patients rare disease medicines
The BioIndustry Association (BIA) has called for a new, reformed pathway to give UK patients access to innovative rare disease medicines.
According to the BIA’s new report, while the UK’s rare disease ecosystem has a solid foundation, more work is needed to build a connected, flexible and risk-proportionate access pathway to turn discovery into delivery for patients.
The findings show the pathway through which rare disease medicines move from regulatory approval to patient access is often fragmented and unpredictable. The report points to the UK’s ranking in the European Federation of Pharmaceutical Industries and Associations (EFPIA)’s Waiting to Access Innovative Therapies (WAIT) Indicator Survey, with the UK ranking second in 2018 for non-oncology orphan drug availability but now ranking tenth.
According to the BIA, the impact of limited access falls heavily on patients, families, and public finances. Delayed diagnosis costs the NHS £340 million ($455 million) annually, with an estimated £14.9 billion ($19.9 billion) loss in tax revenue due to reduced workforce participation.
Elsewhere, in a targeted rare disease stakeholder survey conducted to inform the development of the report, 64% of stakeholders rated access to innovative medicines for rare disease patients as poor or very poor, compared to just 12% for non-rare conditions.
“Navigating life with a rare disease can be incredibly challenging,” said Jane Wall, Managing Director of the BIA.
“For the 3.5 million people living with a rare disease in the UK, the journey from symptoms, to diagnosis, to treatment involves long periods of uncertainty, with only 5% of rare diseases having a licensed treatment. And even when an effective therapy is available to help treat their condition, patients in the UK still face further delays, complexity and uncertainty – with some ultimately missing out on treatment altogether.”
“The BIA, working through its Rare Disease Industry Group (RDIG), is committed to helping deliver meaningful change so more patients can access the medicines they need.”
UK could ‘lead the world’ in rare disease therapies
In the report, the BIA outlined four key solutions to prioritise for reform. They include fostering stronger links between regulators and industry, modernising appraisal and reimbursement, strengthening adoption and implementation, and securing enduring national leadership.
The BIA points out that there is still an opportunity to propel the UK as a global leader in rare diseases innovation. This comes as the National Institute for Health and Care Excellence (NICE) is reviewing its methodology for assessing health benefits and the Medicines and Healthcare products Regulatory Agency (MHRA) is developing a new regulatory pathway for rare disease therapies.
“It is encouraging to see the BIA’s report so clearly reinforce the direction we are taking at MHRA – towards a regulatory landscape for rare diseases that is more agile, more patient-centred and better equipped to bring innovative treatments to those who need them most,” said Lawrence Tallon, CEO of MHRA.
“The UK has all the ingredients to lead the world in rare disease therapies: a world class academic and research base, a single national genomics service and the unparalleled scale and diversity of NHS data.
“The task now is to connect these strengths and harness them through a new regulatory framework, as we announced last month. There is more work ahead, but I want to reassure everyone affected by a rare disease that we are listening, and we are ready to act decisively – driving faster access to pioneering treatments while upholding the highest standards of safety.”
“In these exciting moments for innovation in rare-condition treatments, we need a system where the cutting edge of science – not the decision-making process – is the limiting factor in what our community can expect,” added Nick Meade, CEO of Genetic Alliance UK.
“These ideas are welcome, and this is the right moment to take a strategic overview so we can tackle the barriers that continue to stand in the way of addressing unmet need.”
Bruno Quinney, Content Team, DDW
